asa glp 1 agonists Advises No Longer Holding GLP-1 Agents Prior to Surgery for Most Patients Full article: Targeting metabolic dysfunction

The SURMOUNT-4 randomized clinical trial assessed the effect of tirzepatide discontinuation on the maintenance of weight reduction in adults with obesity and a weight-related complication, excluding diabetes

We have moved far beyond simple glycemic control

Discovery Company

The absolute kilograms drop

This launch underscores the companys Day1 entry into the segment upon patent expiry, demonstrating its readiness to serve unmet patient needs in India

In this study, participants taking orforglipron experienced an average A1C reduction of 2.1% and an average weight loss of 10.1 kilograms at 26 weeks, which was significantly greater than those in the placebo and dulaglutide groups